CUMULATIVE INDEX 1999

Volume 28

March	ADVANCES IN THE MANAGEMENT OF PITUITARY TUMORS, pages 1–246
June	POLYCYSTIC OVARY SYNDROME, pages 247–465
September	HYPOLGLYCEMIC DISORDERS, pages 467–661
December	PEDIATRIC ENDOCRINOLOGY, pages 633–936

Note: Page numbers of article titles are in **boldface** type

Abscesses, pituitary, 107–109
Acanthosis nigricans, in African-American children with type 2 diabetes, 722–723
  in Mexican-American children with type 2 diabetes, 719
  in polycystic ovary syndrome, 403
Acidemia, methylmalonic, hypoglycemia in, 635
Acidophil stem cell adenoma, 23–25
Acne, in polycystic ovary syndrome, 398, 409
Acromegaly, familial, 8
  medical treatment of, **171–190**
    dopamine agonists, 181–183
    somatostatin analogues, long-acting, 177–178
      octreotide, 172–177
      primary versus secondary therapy, 178–181
  pathogenesis of, **1–12**
  pathology of, 16
  surgical management of, 121, 126
ACTH. See *Adrenocorticotropin hormone.*
Activin, in gonadotropin regulation, 305
Acyl-coenzyme A-dehydrogenase deficiency, hypoglycemia in, 632
  very long-chain, hypoglycemia in, 631
Acyl-coenzyme A-dehydrogenase disorder, multiple, hypoglycemia in, 632
Adenohypophysitis, lymphocytic, 71
Adenomas, cortitroph, 28, 35
  hepatic, in glucose 6-phosphatase deficiency, 807
  null cell, 33
  pituitary, classification of, 15–16
    clinical presentation of, 119
    clinically nonfunctioning, 31–35
    definition and epidemiology of, 13–14
    gonadotroph, 31, 33, 223–230
    hormone excess from, 16–31
    imaging of, 54–61
    plurihormonal, 35–36
    surgical management of, 120, 121, 126, 127, 128
    thyrotroph, 26, 230–234
    treatment of, 133–138
  somatotroph, 17
Adolescents, minority, type 2 diabetes in, **709–729**
  obesity in. See *Obesity, in adolescents.*
  polycystic ovary syndrome in, 398
    gonadotropin secretion in, 301–303, 317–318
  with type 1 diabetes mellitus, early diabetes-related complications in, **865–882**
Adrenal gland, androgen regulation by, 271–272
  androgen synthesis in, 265–268
  congenital hyperplasia of, versus polycystic ovary syndrome, 401, 404, 406
  dysfunction of, in polycystic ovary syndrome, 280–284
  tumors of, versus polycystic ovary syndrome, 401–402, 404, 406
Adrenal steroidogenesis, 215
Adrenaline, in glucose counterregulation, 482–484
Adrenarche, 271
  premature role in growth and skeletal maturity, precocious puberty and, 907

Adrenoceptor-blocking and stimulating drugs, hypoglycemic action of, 568
Adrenocorticotropic hormone, excess of, from pituitary adenomas, 27–30
glucocorticoids and, 197–198
in androgen regulation, 268, 271–272
in polycystic ovary syndrome, 281–283
in Cushing's syndrome diagnosis, 194
secretion of, medical therapy and, 211–214
tumors of, imaging of, 58–59
African-American youth, type 2 diabetes in, 720–723
Alcohol consumption, and suicidal insulin injection, 590
in exacerbation of insulin- and sulfonylurea-induced hypoglycemia, 559–561
inducing reactive hypoglycemia, 561
Alcohol-induced hypoglycemia, 555–562
effect of cold on, 558
fasting, 555–558
Alcohol intoxication, hypoglycemia induced by, 640
Alcoholic ketoacidosis, with hypoglycemia, 558–559
Aldosterone, synthesis of, 265–268
Alopecia, androgenetic, in polycystic ovary syndrome, mechanisms of, 410–411
treatment of, 418
Alpha-adrenergic agonists, in gonadotropin regulation, in polycystic ovary syndrome, 308
Amino acid metabolism, disorders of, hypoglycemia in, 634–635
Aminoglutethimide, in Cushing's disease, 216–217
Amylo-1,6-glucosidase deficiency, 811–813
clinical features of, 811–812
diagnosis of, 812–813
hypoglycemia in, 638
management of, 813
Androgenetic alopecia, in polycystic ovary syndrome, mechanisms of, 410–411
treatment of, 418
Androgen(s), excess of. See *Hyperandrogenism*.
insulin resistance related to, 352
metabolism of, in polycystic ovary syndrome, 284–285
receptors for, blockage of. See *Antiandrogens*.
regulation of, 268–272
in adrenal gland, 271–272
in ovary, 268–271
synthesis of, 265–268
in polycystic ovary syndrome, 272–280, 409–410
granulosa cell dysfunction and, 275–278
pathophysiology of, 278–280
theca cell dysfunction and, 273–275
precursor metabolism and, 272
Androstenedione, regulation of, in ovary, 268
synthesis of, 265–268
in polycystic ovary syndrome, 281
Aneurysms, in sellar region, 102–103
imaging of, 71–72
Angiotensin-converting enzyme inhibition/antihypertensive therapy, in type 1 diabetes in children and adolescents, 877
Angiotensin-converting enzyme inhibitors, hypoglycemia following use of, 569
Anovulation, in polycystic ovary syndrome, 398–399
as diagnostic criteria, 380
evaluation of, 404
hypothalamic abnormalities in, 313, 317–318
insulin in, 372–375
insulin-like growth factors in, 330–333
luteinizing hormone abnormalities in, 298
Antiandrogens, in polycystic ovary syndrome, **409–421**
in androgenetic alopecia, 410–411, 418
in hirsutism, 410
cyproterone acetate in, 413–414, 416–417
finasteride in, 413, 417–418
flutamide in, 413, 415–416
mechanisms of, 413–414
principles of, 411–412
spironolactone in, 413–415
Antilipemic agents, in polycystic ovary syndrome, 450–451
Antiplatelet agents, in diabetes mellitus, in polycystic ovary syndrome, 451
Aplasia, 53
Arachnoid cysts, 89–90
Arteriography, for localization of insulinomas, 537, 538
Aspirin, in diabetes mellitus, 446–447
in polycystic ovary syndrome, 451
Atherosclerosis, as complication of diabetes, 869–870
dehydroepiandrosterone and, 445
in insulin resistance, 448–449
in polycystic ovary syndrome, 252, 449
Atractyloside ingestion, hypoglycemia in, 632
Autoimmune diseases, associated with insulin antibodies and hypoglycemia, 606, 609
Autoimmune insulin syndrome, 604–605

Baldness, male pattern, in polycystic ovary syndrome, 398, 403

Beckwith-Wiedemann syndrome, 702–703
  hyperinsulinemia in, 653
  hypoglycemia in, 626
Behavioral problems, in precocious puberty, 909
Beta cell(s), dysfunction of, in polycystic ovary syndrome, 346–347, 424, 427–428
  insulin gene regulation in, biology of, 768, 769
  maturation of, genetic defects of, hypoglycemia in, 627–628
  regulation of insulin secretion in, 648, 696–698
Biguanides, and sulfonylurea-induced hypoglycemia, 567
Blood pressure, high. See *Hypertension.*
Bone mineral density, in precocious puberty, 907
Bordetella pertussis vaccine, hyperinsulinemia and hypoglycemia associated with, 570
Brain, metabolism of plasma glucose by, 468–469
Brain damage, following hypoglycemic coma, 589
Breast cancer, in polycystic ovary syndrome, 257–259
Bromocriptine, 25, 59–60
  in acromegaly, 182–183
  in Cushing's disease, 213–214
  in gonadotroph adenomas, 229–230
  in prolactinomas, 150–152
    long-term considerations, 153–155
    pregnancy and, 158–161
    resistance to, 155–156
    routes and preparations of, 156
    side effects of, 155
    to reduce hyperprolactinemia, 152
    to reduce size of prolactinoma, 152–153
  in thyrotroph adenomas, 234
Bromocriptine-LAR, 183

C-peptide suppression test, in healthy appearing patient, 527–528, 529
Cabergoline, in acromegaly, 182, 183
  in prolactinomas, 152, 157–158
Calcium injection, arterial, insulin response to, in healthy-appearing patient, 529–530
Calcium stimulation, arterial, with hepatic venous sampling, in localization of insulinomas, 540, 541
Cancer, in polycystic ovary syndrome, 255–259
  breast, 257–259
  endometrial, 256–257
  ovarian, 258
Cardiovascular disease, in polycystic ovary syndrome, 251–253, **439–458**
  dehydroepiandrosterone effects on, 445
  diabetes mellitus and, 446–447, 449
  epidemiology of, 439–440
  estrogen effects in, 444
  hormonal effects in, 444–445
  hypertension, 251, 255, 441
  insulin resistance and, 440, 442–449
  lipid profiles and, 441–442
  long-term implications of, 453
  manifestations of, 440
  metabolic factors in, 441–442
  obesity and, 442–444
  testosterone effects on, 444
  treatment of, 449–453
Carney complex, 7, 8
Carnitine deficiency, hypoglycemia in, 630–631
Carnitine palmitoyl-transferase deficiencies, hypoglycemia in, 631
Carotid artery aneurysms, 71–72, 102–103
Cavernous sinus, 47–48
  tumor invasion into, 61
CDKN2A, 3, 4
Central precocious puberty. See *Precocious puberty, central.*
Child(ren), glucose homeostasis in, 619–621
  growth and development of, leptin during, **749–764**
  hyperinsulinemic hypoglycemia in, 688
    genetic mutations as cause of, **647–656**
  hypoglycemia in. See *Hypoglycemia, in infants and children.*
  hypoglycemic disorders in, 623–641
  insulinopenia and diabetic ketoacidosis in, 688–690
  minority, type 2 diabetes in, **709–729**
  obesity in. See *Obesity, in childhood.*
  with type 1 diabetes mellitus, early diabetes-related complications in, **865–882**
Chlorpropamide, 562
Cholesterol, androgen synthesis from, 265–268
  excess of, in polycystic ovary syndrome, 250–251, 440–442, 450–451
Chordomas, parasellar, 91–93
Choristomas, parasellar, 101
Chromosome 11p15, loss of heterozygosity of, hyperinsulinism and, 647, 653
Coagulation disorders, in insulin resistance, in polycystic ovary syndrome, 446–448
Cognitive dysfunction, permanent, associated with hypoglycemia in type 1 diabetes, 883–885

Coma, hypoglycemic, brain damage following, 589
Computed tomography, for localization of insulinomas, 537, 539
of pituitary tumors, 45–46. See also *Imaging of sellar region and pituitary.*
Congenital adrenal hyperplasia, versus polycystic ovary syndrome, 401, 404, 406
Congenital pituitary abnormalities, imaging of, 53
Cori disease. See *Amylo–1,6-glucosidase deficiency.*
Coronary artery disease, in diabetes mellitus, 448–449
in polycystic ovary syndrome, 251–253
Corticotroph adenomas, 28, 35
Corticotroph hyperplasia, 30
Corticotropin releasing hormone stimulation test, 200, 201
Cortisol, excess of, in Cushing's syndrome, versus polycystic ovary syndrome, 401–402, 406
in Cushing's syndrome diagnosis, late-night plasma and salivary, 195–196
urine free, 191–192, 193
in glucose counterregulation, 484–485, 486
synthesis of, 265–268
Craniopharyngiomas, 65, 66–67, 86–87
Craniotomy, for pituitary tumors, 124
CRH stimulation test, 200, 201
Crooke's cell adenoma, 29–30
Cushing's disease, diagnosis of, **191–210**
medical therapy of, **211–222**
future prospects, 219
site of action, adrenal, 214–218
hypothalamic-pituitary, 211–214
peripheral receptor, 218–219
pathology of, 27–30
surgical management of, 121, 127
Cushing's syndrome, differential diagnosis of, CRH stimulation test in, 200, 201
desmopressin stimulation test in, 204–206
high-dose dexamethasone suppression test in, 196–200
inferior petrosal sinus sampling in, comparison with imaging, 200, 202–204
endogenous, diagnosis of, late-night plasma and salivary cortisol in, 195–196
low-dose dexamethasone testing in, 192, 194–195
urine free cortisol in, 191–192, 193
hypercortisolism in, versus polycystic ovary syndrome, 401–402, 406
imaging ACTH tumors in, 58
versus polycystic ovary syndrome, 401–402, 406
Cyproheptadine, in Cushing's disease, 212–213
Cyproterone acetate, in polycystic ovary syndrome, in hirsutism, 413–414, 416–417
Cystic fibrosis, diabetes mellitus in, **787–800**
glucose tolerance categories in, 788
Cysts, epidermoid, 90
of sellar and parasellar region, 85–86
arachnoid, 89–90
craniopharyngiomas, 65, 66–67, 86–87
epidermoid, 90
Rathke's cleft, 53, 65, 87–89
ovarian, multiple. See *Polycystic ovary syndrome*
Cytochrome P–450, mitochondrial forms of, 827–834

Dehydroepiandrosterone, synthesis of, 265–268
in adrenal gland, 271–272
in polycystic ovary syndrome, 281–284, 399–400
cardiovascular risks in, 445
measurement of, 403–404
11-Deoxycortisol, synthesis of, in polycystic ovary syndrome, 283
Dermoid tumors, parasellar, 95
Desmopressin stimulation test, 204–206
Dexamethasone androgen-suppression test, in polycystic ovary syndrome, 273–274, 281
Dexamethasone-CRH test, 194–195
Dexamethasone suppression test, high-dose, 196–200
low-dose, 192, 194–195
Dextrinosis, limit. See *Amylo–1,6-glucosidase deficiency.*
Diabetes insipidus, 83–84, 99
germinomas and, 93–94
pituitary bright spot and, 72
Diabetes mellitus, cardiac disease in, 869
complications of, macrovascular, 868–870
microvascular, 866–868
natural history of, 866–870
hypertension in, 869
in cystic fibrosis, **787–800**
abnormal glucose tolerance in, 790–791
description of, 789–790
diagnostic criterion for, 790
dietary management of, 796
future directions in, 797–798
medical management of, 793–796
pathophysiology of, 789–790
psychologic aspects of, 796–797
screening recommendations for, 791–793, 794

in polycystic ovary syndrome, 249–250, 342–344
cardiovascular risks of, 442–444, 446–447
epidemiology of, 424, 427–428
in pregnancy, 254–255
increased insulin secretion in, 346–347, 399
treatment of, 428–436, 450–451
insulin-dependent. See *Diabetes mellitus, type 1.*
maturity-onset, of young. See *MODY syndromes.*
monogenic, in youth, **765–785**
nephropathy in, 867–868
neuropathy in, 868
retinopathy in, 866–867
type 1, autoimmune disease development in, models of, 842–850
bystander T-cell proliferation hypothesis of, 845–846
CD4+ versus CD8+ cells in etiopathogenesis of, 849–850
children and adolescents with, angiotensin-converting enzyme inhibition/antihypertensive therapy in, 877
diabetes-related complications of, primary prevention and secondary intervention in, 876–877
risk factors for, 870–873
early diabetes-related complications in, **865–882**
intensive mnaagement in, 876
children with, hypoglycemia in, **883–900**
acute, implications of, 890
and permanent cognitive dysfunction, 883–885
classification and prevalence of, 892–895
management of, 895–896
transient reductions of mental efficiency in, 885–890
unawareness of, and autonomic failure, 891–892
duration of, complications and, 870
family history of, complications related to, 871
hyperlipidemia in, 871
immunology of, **841–864**
in puberty, acceleration of complications and, 872–873
intervention strategies in, 852–859
metabolic control of, complications and, 870–871
molecular mimicry-activated T-cell proliferation concept of, 842–845
prevention strategies in, 850–852
screening for complications of, in adolescents, 873–876
smoking and, 872
superantigen-mediated T-cell proliferation hypothesis of, 846–849
treatment of, 850
type 2, in children and adolescents, insulin in, 723–724
in minority children and adolescents, **709–729**
in youth, African-American experience with, 720–723
clinical characteristics of, 710–711
epidemiology of, 710–712
metabolic/biochemical characteristics of, 712
Mexican-American experience with, 717–719
Pima Indian experience with, 712–717
therapy in, 723–724
youth-onset, common forms of, compared, 766–768
diagnostic classification of, 781, 782
Diabetic ketoacidosis, and insulinopenia, in children, 688–690
Diarrhea, severe, hypoglycemia in, 640
Diazoxide, in autoimmune hypoglycemia, 611
in hyperinsulinemia, in polycystic ovary syndrome, 428
in sulfonylurea overdose, 593
Dihydrotestosterone, inhibitors of. See *Antiandrogens.*
synthesis of, 272
Disopyramide, hypoglycemic properties of, 568
Dopamine, in gonadotropin regulation, in polycystic ovary syndrome, 307–308
Dopamine agonists, in acromegaly, 181–183
in Cushing's disease, 213–214
in gonadotroph adenomas, 229–230
in prolactinomas, bromocriptine, 150–156
compared for reducing tumor size, 152
miscellaneous, 156–158
pregnancy and, 158–161
in thyrotroph adenomas, 234
Drug-induced hypoglycemia, **555–577**
Drugs, associated with hypoglycemia, 566–571
associated with insulin antibodies and hypoglycemia, 606, 608–609

Ectopic posterior pituitary, 72
Empty sella, 65–68
Endometrium, cancer of, in polycystic ovary syndrome, 256–257

Endometrium *(Continued)*
hyperplasia of, in polycystic ovary syndrome, 397–398
Epidermoid cysts, 90
Erythroblastosis fetalis, hypoglycemia in, 626
Estradiol, in polycystic ovary syndrome, measurement of, 444
production of, 275–276, 367–368
production of, insulin effects on, 362–363, 366–368, 371–372
regulation of, 268–269
Estrogen(s), deficiency of, in polycystic ovary syndrome, cardiovascular risks in, 444
in gonadotropin regulation, in polycystic ovary syndrome, 308, 310–316
secretion of, insulin effects on, 362–363
Estrone hypothesis, of polycystic ovary syndrome pathogenesis, 308
Euglycemic glucose clamp studies, of insulin action, in polycystic ovary syndrome, 344–345

Familial syndromes, of pituitary tumors, 7–8
Family studies, of polycystic ovary syndrome. See *Polycystic ovary syndrome, phenotypic studies of.*
Fasting, plasma substrate and hormonal changes with, 664–665
Fat, body, distribution of, in obesity in adolescents, 738–739
Fatty acids, free, in glucose counterregulation, 480, 487–488
oxidation of, disorders of, hypoglycemia in, 629–632
pathways of, 629–630
Fetal development, dopamine agonists and, 158–159
Fibrinolysis, impaired, in insulin resistance, in polycystic ovary syndrome, 447–448, 452
Fibroblast growth factor–2, 5
Fibroblast growth factor–4, 5–6
Finasteride, in hirsutism, in polycystic ovary syndrome, 413, 417–418
Flutamide, in hirsutism, in polycystic ovary syndrome, 413, 415–416
Follicle-stimulating hormone, gonadotropin interactions with, in granulosa cells, 364–367
in androgen regulation, 268–269, 271
in polycystic ovary syndrome, 275–276
in gonadotroph adenomas, 223–226
secretion of, in hyperandrogenemia, in adolescents, 301–302
in ovulatory menstrual cycles, 296–297
in polycystic ovary syndrome, 297–299, 302, 304–306
estrogen-progesterone feedback and, 310, 312
estrogens and, 308
hypothalamic regulation and, 317–318
insulin and, 309–310, 368–371
measurement of, 404
Follicular fluid, insulin-like growth factors in, 327–328, 364
Follistatin, in gonadotropin regulation, 305
Food intake, role of leptin in, 756–759
Forbes disease. See *Amylo–1,6-glucosidase deficiency.*
Free fatty acids, in glucose counterregulation, 480, 487–488
Fructose–1,6-diphosphatase deficiency, hypoglycemia in, 639
Fructose intolerance, hereditary, hypoglycemia in, 636

Galactosemia, hypoglycemia in, 636
Gallstones, octreotide and, 176–177
Gamma-aminobutyric acid, 145
Gamma-aminobutyric acid agonists, in Cushing's disease, 214
Gamma knife surgery, for pituitary tumors, **133–142**
after surgery, 128–129
complications of, 139–140
experience with, 138–139, 140
goals of, 136
indications for, 136–138
methodology of, 135–136
Gamma Knife Unit, 134
Ganglion cell tumors, 100–101
Genetic factors, in polycystic ovary syndrome, 354–356, 391–392
Genetic mutations, as cause of hyperinsulinemic hypoglycemia in children, **647–656**
Germinomas, parasellar, 93–95
Giant cell granuloma, pituitary adenoma versus, 105
Gigantism, pathology of, 16
Glibenclamide, 562, 563
Glucagon, in glucose counterregulation, 476–482
Glucocorticoids, in hirsutism, in polycystic ovary syndrome, 412
Glucokinase gene, activating mutation of, 651–652
Gluconeogenesis, and ketogenesis, 678–683
disorders of, hypoglycemia in, 639–641
enzymatic and fundamental defects in, 690–692
glucose production by, 679–683

Glucose, administration of, in factitious hypoglycemia, 593
endogenous production of, 675
liver and kidney as sources of, 470–471
excess of, in polycystic ovary syndrome, 249–250, 399, 450
exogenous, 683
fetal requirements for, 686–688
hepatic autoregulation of, in glucose counterregulation, 488
homeostasis, during fasting, 685
during meal absorption, 684–685
in children, abnormalities of, 688–692
in infants and children, 619–621
in absorptive state, 470
in postabsorptive state, 469–470
in utero requirements for, 686–688
metabolism of, pathways of, 620
physiology of, 469–471
normal concentration of, prerequisites necessary for maintenance of, 663
plasma, brain in metabolism of, 468–469
levels of, in healthy-appearing patient, 519–520
plasma concentration of, during fasting, 664–665
production of, by gluconeogenesis, 679–683
rate of disappearance of, 670
total, of children, in relationship to body and brain weight, 668–669
use of, insulin-dependent, 672–675
used by brain and nonbrain tissues from infancy to adulthood, 669
Glucose 6-phosphatase, 675–676
Glucose 6-phosphatase deficiency, 805–811
clinical features of, 806–808
diagnosis of, 808
hepatic adenomas in, 807
hypoglycemia in, 637–638
management of, 810–811
nephropathy in, 807
osteoporosis in, 808
Glucose counterregulation, mechanisms of, 476–488
to hypoglycemia, physiology of, **467–493**
Glucose counterregulatory system, 472–473
architecture of, 473
Glucose disposal, non-insulin-dependent, 671–672
Glucose hemostasis, in children, regulation of, **663–694**
Glucose-insulin homeostasis, in obesity in adolescents, 738–739
Glucose intolerance. See also *Diabetes mellitus.*
in polycystic ovary syndrome, 249–250, 342–344
cardiovascular risks of, 443–444, 446–447
pathogenesis of, 424–428
treatment of, 428–436, 450
Glucose pool, 665–668
in glucose space, 669–670
Glucose tolerance test, in polycystic ovary syndrome, 405, 425–428
Glucose tolerance testing, oral, 502–503, 504
Glucose transporters, 670–671
defect in, hypoglycemia in, 641
Glycemic thresholds, falling plasma glucose concentrations and, 497–498
Glycogen, synthesis and breakdown of, 802
Glycogen debranching enzyme deficiency. See *Amylo-1,6-glucosidase deficiency.*
Glycogen phosphorylase deficiency, 813–815
clinical features of, 814
diagnosis of, 815
management of, 815
Glycogen storage disease(s), **801–823**
biochemical characteristics of, 809
hepatic, 804
hypoglycemia in, 637–639
type I. See *Glucose 6-phosphatase deficiency.*
type III. See *Amylo-1,6-glucosidase deficiency.*
type IX. See *Phosphorylase kinase deficiency.*
type VI. See *Glycogen phosphorylase deficiency.*
Glycogen synthase deficiency, clinical features of, 803
diagnosis of, 805
hypoglycemia in, 639
management of, 805
Glycogen synthesis, regulation of, 676–678
Glycogenolysis, regulation of, 676–678
Glycogenolysis cascade, 801, 803
Glycogenoses. See *Glycogen storage disease(s).*
Gonadotroph adenomas, 31, 33
clinical presentation of, 224–225
evaluation of, 225–226
hormonal classification of, 223
in vitro and in vivo studies, 224
treatment of, medical therapy, 227–230
radiation therapy, 227
surgery, 226–227
Gonadotropin. See also *Follicle-stimulating hormone; Luteinizing hormone.*
pubertal, and sex steroid secretion, 905
Gonadotropin-associated peptide, 145
Gonadotropin excess, from pituitary adenomas, 31
Gonadotropin-releasing hormone, response to, in polycystic ovary syndrome, 298

Gonadotropin-releasing hormone *(Continued)*
androgens and, 308–309
estrogen-progesterone feedback and, 310–316
estrogens and, 308
insulin and, 309–310
pulse stimuli in, 304–306, 313, 317–318
Gonadotropin-releasing hormone agonist challenge test, in polycystic ovary syndrome, 273–275, 281–282
Gonadotropin-releasing hormone analogues, in central precocious puberty, 908–912
impact on growth, 908–909
untimely pubertal development and, 909
in gonadotroph adenomas, 230
Granulomatous processes, of sellar region, 103–109
Granulosa cells, androgen synthesis in, 268, 270–271
dysfunction in polycystic ovary syndrome, 275–280
insulin action in normal, 362–364
gonadotropin interaction with insulin in, 364–367
in polycystic ovary syndrome, 368–371
in polycystic ovary syndrome, 367–368
gonadotropin interactions with, 368–371
receptor function and, 371–372
insulin-like growth factor expression in, 326, 364
Graves' disease, hyperthyroidism versus, 231
Growth, and growth potential in relation to skeletal age, 906
Growth factor 1 axis, growth hormone/insulin-like, in obesity in adolescents, 742–744
Growth factors, insulin-like. See *Insulin-like growth factor family.*
Growth hormone, dopamine agonist effects on, 182–183, 184
excess, from pituitary adenomas, 16–21
in glucose counterregulation, 484
insulin-like growth factor 1 axis, in obesity in adolescents, 742–744
levels in acromegaly, 171–172
somatostatin analogue effects on, 173–174, 180–181, 184
Growth hormone–releasing hormone, in acromegaly, 1–2
Growth rate, progressive precocious puberty and, 906
Gsp mutations, in pituitary tumors, 3, 4
H-ras, in pituitary tumors, 4
Hair, androgenetic loss of, in polycystic ovary syndrome, mechanisms of, 410–411
treatment of, 418
excessive growth of. See *Hirsutism.*
Hamartomas, hypothalamic, 100
Hand-Schüller-Christian disease, 105, 107
Headache, octreotide and, 175
Heart disease, hypoglycemia in, 641
in diabetes, 868–869
Hemoglobin, glycated, in healthy appearing patient, 529, 530
Hepatic adenomas, in glucose 6-phosphatase deficiency, 807
Hepatorenal glycogenesis. See *Glucose 6-phosphatase deficiency.*
Hirsutism, definition of, 410
in polycystic ovary syndrome, 398, 410
as diagnostic criteria, 380, 383–386
evaluation of, 403, 405–406
treatment of, cyproterone acetate in, 413–414, 416–417
finasteride in, 413, 417–418
flutamide in, 413, 415–416
principles of, 411–412
spironolactone in, 413–415
Histiocytosis, infundibular, 69
Histiocytosis X, pituitary adenoma versus, 105, 107
Homicide, by insulin-induced hypoglycemia, 591–593
Hormone excess from pituitary adenomas, 16–31, 35–36
Hormones, deficiencies of, hypoglycemia in, 634
rapid-acting, in glucose counterregulation, 476–484
slow-acting, in glucose counterregulation, 484–485, 486
hst, in pituitary tumors, 4
Human chorionic gonadotropin, response to, in polycystic ovary syndrome, 278
Hydrocortisone, in factitious hypoglycemia, 593
3-Hydroxy–3-methyl glutaric acidemia, hypoglycemia in, 635
17-Hydroxylase/17,20 lyase, in androgen regulation, 269
in polycystic ovary syndrome, 273, 279
21-Hydroxylase deficiency, versus polycystic ovary syndrome, 401, 404, 406
17-Hydroxyprogesterone, production of, in polycystic ovary syndrome, 283, 404
5-Hydroxytryptophan, hypoglycemia associated with use of, 570
Hyperammonemia, and hyperinsulinism, syndrome of, 647, 652–653

Hyperandrogenism, following central precocious puberty, 913–915
from androgen-producing tumors, versus polycystic ovary syndrome, 401–402, 404, 406
in adolescents, pulsatile gonadotropin secretion in, 301–303, 317–318
in hyperthecosis, 401
in polycystic ovary syndrome, 248, 398, 399–400, 409–410
abnormal steroid metabolism and, 284–285
as diagnostic criteria, 380–381, 384
female relatives status and, 387–391
genetic factors in, 354–355
hyperinsulinemia and, 353–354
in adrenal gland dysfunction, 280–284
in granulosa cell dysfunction, 275–278
in theca cell dysfunction, 273–275
insulin-like growth factor family in, 332–333
pathogenesis of, 278–280
treatment of, **409–421**, 428–429, 434, 436
insulin resistance in, 352
Hypercholesterolemia, in polycystic ovary syndrome, 250–251, 440–442
treatment of, 450–451
Hypercortisolism. See *Cushing's syndrome.*
Hyperglycemia, in polycystic ovary syndrome, 249–250, 399
treatment of, 450
Hyperinsulinemia, 501
associated with *Bordetella pertussis* vaccine, 570
hypoglycemia in, 624–628
in polycystic ovary syndrome, cardiovascular risks of, 445–449
clearance rate and, 347
epidemiology of, 250
evaluation of, 399, 400, 405
hyperandrogenism and, 353–354, 362–363
insulin action and, 342–344
secretion and, 346–347, 424–428
treatment of, 428–436, 452–453
Hyperinsulinism, and hyperammonemia, syndrome of, 647, 652–653
autosomal dominant, hypoglycemia in, 627
congenital, 647
drug-induced, in children, hypoglycemia in, 628
in infants of diabetic mothers, hypoglycemia associated with, 626
loss of heterozygosity of chromosome 11p15 and, 647, 653
recessively inherited, hypoglycemia in, 627
Hyperinsulinism/hyperammonia syndrome, hypoglycemia in, 627–628
Hyperlipidemia, in polycystic ovary syndrome, treatment of, 450–451
in type 1 diabetes, 871
Hyperplasia, pituitary, corticotroph, 30
lactotroph, 25
pathologic, 110–111
physiologic enlargement of, 110
somatotroph, 20–21
thyrotroph, 25, 27
Hyperprolactinemia, 21–26. See also *Prolactinomas.*
bromocriptine therapy, 152, 154
etiology, 145–146
in nonpituitary sellar lesions, 83
Hypertension, in diabetes, 869
in polycystic ovary syndrome, 251, 441
in pregnancy, 255
treatment of, 451
Hyperthecosis, versus polycystic ovary syndrome, 400–401
Hyperthyroidism, Graves' disease versus, 231
Hypoestrogenemia, in polycystic ovary syndrome, 444
Hypoglycemia, acute, model of, 473–475
alcohol-induced, 555–562
effect of cold on, 558
alcoholic ketoacidosis with, 558–559
as defense against culpability, 594–595
associated with *Bordetella pertussis* vaccine, 570
autoimmune, **603–618**
caused by insulin antibodies, 603–611
clinical presentation of, 605–606
conditions associated with, 606
course and treatment of, 611
diagnosis of, 610–611
etiology of, 608–610
laboratory findings in, 606–607
pathogenesis of, 607–608
caused by insulin receptor antibodies, 611–615
clinical presentation of, 612
course and treatment of, 614–615
diagnosis of, 614
laboratory findings in, 612–613
pathogenesis of, 613–614
death from, 583–584
forensic aspects of, 585–588
methodologic considerations in investigation of, 588
definition of, 471–472
drug-induced, **555–577**
drugs associated with, 566–571
experimental models of, 473–476
factitious, and felonious, **579–601**
insulin-induced, 579–582, 589
sulfonylurea-induced, 582–583
treatment of, 593–594
stage 1, 593–594

Hypoglycemia *(Continued)*
stage 2, 594
fasting, alcohol-induced, 555–558
and postprandial, 503–504
glucose counterregulation to, physiology of, **467–493**
hyperinsulinemic, autosomal dominant, 651
autosomal recessive, 649–651
genetic forms of, 647, 648
in children, 687–688
genetic mutations as cause of, **647–656**
of infancy, **695–708**
autosomal dominant persistent, 699–700
autosomal recessive persistent, 698–699
clinical correlation and therapeutic implications in, 703
genetic forms of, classification of, 696
molecular defects in, correlation of clinical features with, 705
sporadic persistent, 700–702
persistent, of infancy, 647
surgical aspects of, **533–554**
hyperinsulinism in, in infants of diabetic mothers, 626
hypoketotic, in disorders of fatty acid oxidation, 630
in asphyxiated infants, 626
in children with type 1 diabetes. See *Diabetes mellitus, type 1, children with, hypoglycemia in.*
in infants and children, **619–646**
adverse side effects of, 622
definition of, 621
diagnostic approach to, 622–623, 624
signs and symptoms of, 621–622
treatment of, 623
in insulin overdose, 580–582
insulin-induced, and sulfonylurea-induced, alcoholic exacerbation of, 559–561
homicide by, 591–593
postmortem diagnosis of, 585–588
postprandial, and fasting, 503–504
following pancreas transplantation, 610
profound, toleration of, 583
prolonged, model of, 475–476, 477, 478, 479, 480
reactive, 502, 504
alcohol-induced, 561
in alcoholic persons, 561–562
sensors of, 472–473
sulfonylurea-induced, and insulin-induced, alcoholic exacerbation of, 559–561
diagnosis of, 565–566
factors predisposing to, 563
symptoms of, 562–563
treatment of, 566
vital statistics in, 564, 565
symptoms of, 495–497
and unawareness of, **495–500**
unawareness of, induction/development of, 498
Hypoglycemic disorders, **467–656**
classification of, **501–517**
clinical classification of, 505–509
diagnostic approach to adults with, **519–532**
in healthy-appearing patient, 519–530
in ill-appearing patient, 530–531
in infants and children, 623–641
postprandial symptoms of, 502–505
Hypophysitis, granulomatous, pituitary adenoma versus, 105
lymphocytic, 107
Hypothalamic glioma, 96–97
Hypothalamic GRH-producing tumors, 21
Hypothalamic hamartomas, 100
Hypothalamus, gonadotropin regulation by, in polycystic ovary syndrome, 307–309, 313, 317–318
role in pituitary tumors, 1–2

Incidentalomas, pituitary, imaging of, 73–74
Infant(s), asphyxiated, hypoglycemia in, 626
glucose homeostasis in, 619–621
hyperinsulinemic hypoglycemia in. See *Hypoglycemia, hyperinsulinemic, of infancy.*
hypoglycemia in. See *Hypoglycemia, in infants and children.*
hypoglycemic disorders in, 623–641
of diabetic mothers, hyperinsulinism in, hypoglycemia associated with, 626
premature, hypoglycemia in, 632
small for gestational age, hypoglycemia in, 633
Infections, of sellar region and pituitary, 103–109
imaging of, 71
Inferior petrosal sinus sampling, 200, 202–204
Infertility. See also *Anovulation.*
in polycystic ovary syndrome, 398–399
Inflammation, of sellar region and pituitary, 103–109
imaging of, 71
Infundibular histiocytosis, 69
Infundibulomas, 101
Inhibin, in androgen regulation, 270

in polycystic ovary syndrome, 280
in gonadotropin regulation, in polycystic ovary syndrome, 302
Insulin, action and secretion of, during development of obesity in childhood, 732–735
action of, gonadotropin interactions with, in granulosa cells, 364–367
in polycystic ovary syndrome, **341–359, 361–378**
anovulation related to, 372–373
decreased clearance of, 347
euglycemic glucose clamp studies of, 344–345
glucose tolerance and, 342–344
gonadotropin interactions with, 368–371
hypothesis for, 352–356
molecular mechanisms of, 347–352
on granulosa cells, 367–372
on stromal cells, 375
on theca cells, 373–375
receptor function and, 349–352, 371–372
secretion patterns and, 346–347
on granulosa cells, 362–364
in polycystic ovary syndrome, 367–372
receptor function and, 371–372
target tissues for, 348–349
attempted suicide using, alcohol consumption and, 590
patients alive following, 588–590
excess of. See *Hyperinsulinemia.*
factitious hypoglycemia induced by, 579–582, 589
hypoglycemia induced by, in homicide, 591–593
in type 2 diabetes in children and adolescents, 723–724
overdose of, hypoglycemia associated with, 580–582
receptors for, in polycystic ovary syndrome, 349–352, 424
normal function of, 347–349
reduction of, in polycystic ovary syndrome, drugs for, 428–436
resistance to, in polycystic ovary syndrome, 341, 399, 400
cardiovascular disease in, 440, 442–449
causal association of, 352–354
decreased clearance in, 347
euglycemic glucose clamp studies of, 344–345
evaluation of, 405
genetic association in, 354–356
glucose tolerance and, 342–344
hypothesis for, 352–356
increased secretion in, 346–347
molecular mechanisms of, 347–352
pathogenesis of, 424–428
treatment of, 428–436
secretion of, ambient glucose concentration and, 672–675
in polycystic ovary syndrome, 424–428
regulation of, in pancreatic beta cells, 696–698
sensitizers for, in polycystic ovary syndrome, 428, 434–436
suicide using, 590
Insulin antibodies, causing hypoglycemia. See *Hypoglycemia, caused by insulin antibodies.*
in healthy appearing patient, 528–529
Insulin-dependent diabetes mellitus. See *Diabetes mellitus type 1.*
Insulin-like growth factor–1, octreotide effects on, 173–174, 180, 181, 184
somatostatin analogue effects on, 173–174, 180, 181, 184
Insulin-like growth factor family, in androgen regulation, 269–271
in normal ovary, 326–330, 364
in polycystic ovary syndrome, 330–333, 353–354
Insulin receptor antibodies, causing hypoglycemia. See *Hypoglycemia, caused by insulin receptor antibodies.*
Insulinoma(s), 509–513
as cause of hypoglycemia, 501–502
benign, Mayo Clinic experience with, 534, 535
diagnosis of, 535–536
history of, 535
incidence of, 533
localization of, 536–544
arterial calcium stimulation with hepatic venous sampling in, 540, 541
arteriography for, 537, 538
computed tomography for, 537, 539
endoscopic ultrasonography in, 542
intraoperative ultrasonography in, 542–543
preoperative transabdominal ultrasonography in, 541–542
transshepatic portal venous sampling for, 539–540
malignant, 551
surgical management of, 544–549
complications of, 548–549
intraoperative management in, 544–545
no tumor identified in, management following, 547–548
postoperative management in, 549
preoperative preparation for, 544
results of, 546–547
technique of, 545–546

Insulinoma(s) *(Continued)*
symptoms of hypoglycemia in, 497
Insulinopenia, and diabetic ketacidosis, in children, 688–690
Islet cell adenoma, 703

Jamaican vomiting sickness, hypoglycemia in, 632

Ketoacidosis, alcoholic, with hypoglycemia, 558–559
diabetic, and insulinopenia, in children, 688–690
Ketoconazole, in Cushing's disease, 217–218
Ketogenesis, gluconeogenesis and, 678–683
Ketotic hypoglycemia, as cause of childhood hypoglycemia, 633–634
Kir6.2 genes, mutations of, and autosomal recessive hyperinsulinemic hypoglycemia, 649–650

Lactotroph adenomas, 22
Lactotroph hyperplasia, 25
Lanreotide, slow-release, 178, 179
Leptin(s), concentrations of, in fetus and neonate, 751, 752
during childhood growth and development, **749–764**
levels of, in obesity in adolescents, 739–741, 742
physiologic functions of, 756–760
role of, in food intake, 756–759
in metabolism and energy expenditure, 759
in puberty, 760
serum concentration of, gender differences in, factors responsible for, 751–755, 756, 757–759
spontaneous secretion of, 749–751
Limit dextrinosis. See *Amylo–1,6-glucosidase deficiency.*
Lipoprotein(s), profiles of, in polycystic ovary syndrome, 250–251, 440–442
Liver, diseases of, hypoglycemia in, 641
glucose production in, in polycystic ovary syndrome, 345
Liver phosphorylase deficiency, hypoglycemia in, 638–639
Luteinizing hormone, gonadotropin interactions with, in granulosa cells, 364–367
in androgen regulation, 268–271
in polycystic ovary syndrome, 278–280
in gonadotroph adenomas, 223–226
secretion of, in hyperandrogenemia, in adolescents, 301–303, 317–318
in ovulatory menstrual cycles, 296–297
in polycystic ovary syndrome, 297–301, 298, 303, 304–306, 400
androgens and, 308–309
estrogen-progesterone feedback and, 310–316
estrogens and, 308
familial aspects of, 388
hypothalamic regulation and, 307–309, 313, 317–318
insulin and, 309–310, 354, 368–371, 372–373
measurement of, 404
neurotransmitters and, 307–308
Luteinizing hormone-to-follicle-stimulating hormone ratio, in polycystic ovary syndrome, 404
Lymphocytic hypophysitis, 107
Lymphomas, parasellar, 101

Macroadenomas, imaging, 54, 55
Magnetic resonance imaging, of pituitary tumors, 46–53, 85
Malaria, severe, hypoglycemia in, 640
Mammosomatotroph adenomas, 17–18, 35
Maple syrup urine disease, hypoglycemia in, 635
McCune-Albright syndrome, 8, 20
Meckel's cave, 49
MEN-1. See *Multiple endrocrine neoplasia type 1.*
MEN-1 gene, 3, 4, 147
MEN-1 syndrome, 548, 549–550
Menarche, early, in central precocious puberty, therapy of, 909
menstrual irregularity after, in polycystic ovary syndrome, 398
Meningiomas, of sellar and parasellar regions, 65, 68, 97–99
Menstrual cycles, dysfunctional. See also *Anovulation.*
evaluation of, 404
in polycystic ovary syndrome, 248, 397–398
as diagnostic criteria, 380, 383–386
ovulatory, gonadotropin secretion during, 296–297
Mental efficiency, transient reductions in, acute hypoglycemia and, 885–890
Metabolism and energy expenditure, role of leptins in, 759
Metastases, pituitary, 99–100
Metformin, and sulfonylurea-induced hypoglycemia, 567
in hyperinsulinemia, in polycystic ovary syndrome, 428–435, 452–453

Methylmalonic acidemia, hypoglycemia in, 635
Metyrapone, in Cushing's disease, 216
Mexican-American youth, type 2 diabetes in, 717–719
Microadenomas, imaging of, 54, 55–56
Microalbuminuria, screening for, in adolescents with type 1 diabetes, 874
Mifepristone, in Cushing's disease, 218–219
Mitochondrial trifunctional protein deficiency, hypoglycemia in, 631
Mitotane, in Cushing's disease, 215–216
Mixed meal test, in healthy appearing patient, 527
MODY syndromes, atypical diabetes mellitus in, 776–779, 780
  classification of, 765–768
  clinical, genetic, and metabolic characteristics of, 768–769, 770
  definition and history of, 765
  MODY1, 769–773
  MODY2, 773–774
  MODY3, 774–775
  MODY4, 775–776
  MODY5, 776
  treatment of, 779–781
Monoamine oxidase inhibitors, hypoglycemia associated with use of, 570
Mouse models of pituitary tumors, 6
Mucoceles, sphenoid sinus, 109–110
Multiple endocrine neoplasia type 1, 7, 8, 548, 549–550
  prolactinomas in, 147
Myoblastomas, parasellar, 101

National Cooperative Program in Infertility Research, polycystic ovary syndrome phenotyping in, 387–391
Nelson's syndrome, 28, 127
Nephropathy, in diabetes, 867–868
  in glucose 6-phosphatase deficiency, 807
Nesidioblastosis, 647. See *Hypoglycemia, hyperinsulinemic.*
Neuroendocrine aspects, of polycystic ovary syndrome. See *Follicle-stimulating hormone; Luteinizing hormone.*
Neuropathy, in diabetes, 868
Neurotransmitters, hypothalamic, in gonadotropin regulation, in polycystic ovary syndrome, 307–308
  in glucose counterregulation, 486–487
Noninsulinoma pancreatogenous hypoglycemia syndrome, 550–551
Nonpituitary lesions, parasellar and intrasellar, classification of, 83
Noradrenaline, in glucose counterregulation, 486–487
Norepinephrine, in gonadotropin regulation, in polycystic ovary syndrome, 308
Null cell adenomas, 33

Obesity, in adolescents, body fat distribution and glucose-insulin homeostasis in, 738–739
  growth hormone/insulin-like growth factor 1 axis in, 742–744
  leptin levels in, 739–741, 742
  in African-American children with type 2 diabetes, 721–722
  in childhood, development of, insulin action and secretion during, 732–735
  metabolic impact of, **731–747**
  pancreatic beta cells in, 735–738
  in Mexican-American children with type 2 diabetes, 719
  in Pima Indian youth with type 2 diabetes, 714–717
  in polycystic ovary syndrome, 285
  cardiovascular disease in, 442
  epidemiology of, 248–249, 442
  evaluation of, 399
  glucose intolerance and, 343–344
  hyperinsulinemia and, 346–347, 423–424, 426–427
  treatment of, 429, 433, 436
  hypertension in, 441
  in pregnancy, 255
  insulin resistance and, 344–345
  insulin status and, 400
  physical examination of, 403
Octreotide, 18–20
  biochemical effects on GH and IGF–1, 173–174
  in acromegaly, adverse effects, 176–177
  effect on clinical symptoms, 174–175
  primary versus secondary therapy, 178–181
  tumor shrinkage with, 175
  in autoimmune hypoglycemia, 611
  in Cushing's disease, 214
  in gonadotroph adenomas, 227–229
  in sulfonylurea overdose, 593
  in thyrotroph adenomas, 233–234
  pharmacokinetics, 172
Octreotide-LAR, 177, 178
Oligomenorrhea, in polycystic ovary syndrome, 248, 397–398
  as diagnostic criteria, 380, 383–386
  evaluation of, 404
Oncogene mutations, 2–3
Opioids, in gonadotropin regulation, in polycystic ovary syndrome, 307–308

Optic nerve glioma, 69, 95–96
Oral contraceptives, in polycystic ovary syndrome, 311, 313
  for hirsutism, 413–414, 416–417
Osteoporosis, in glucose 6-phosphatase deficiency, 808
Ovaries and uterus, ultrasound estimation of size of, in precocious puberty, 907
Ovary, androgen regulation by, 268–271
  androgen synthesis in, 265–268
  cancer of, in polycystic ovary syndrome, 258
  dysfunction of, in polycystic ovary syndrome, 272–280
    granulosa cell, 275–278
    pathogenesis of, 278–280
    theca cell, 273–275
  granulosa cells of. See *Granulosa cells.*
  hyperthecosis of, versus polycystic ovary syndrome, 400–401
  insulin-like growth factor family in, 326–330, 364
    in polycystic ovary syndrome, 330–333, 353–354
  polycystic disease of. See *Polycystic ovary syndrome.*
  theca cells of. See *Theca cells.*
  tumors of, versus polycystic ovary syndrome, 401–402, 404, 406
Ovulatory menstrual cycles, gonadotropin secretion during, 296–297
Oxaloacetate production, effects of free fatty acid oxidation on, 679
P450 Oxidoreductase, 827
Oxytocin, 53

Pancreas, lesions of, focal, hypoglycemia in, 628
  transplantation of, postprandial hypoglycemia following, 610
Pancreatectomy, surgical, in hyperinsulinemic hypoglycemia of infancy, 704
Pancreatic-adrenocortical-pituitary clamp, in glucose counterregulation, 476
Pancreatic beta cells. See *Beta cell(s).*
Paracetamol, hypoglycemia associated with use of, 569
Patient(s), healthy appearing, hypoglycemic disorders in, 519–530
  ill appearing, hypoglycemic disorders in, 530–531
Pediatric endocrinology, **663–918**
Pentamidine, hypoglycemia following use of, 569
Peptide histidine methionine, 145
Pergolide, in acromegaly, 182
  in prolactinomas, 152, 157
Phenformin, and sulfonylurea-induced hypoglycemia, 567
Phenotypes, of polycystic ovary syndrome. See *Polycystic ovary syndrome, phenotypic studies of.*
Phosphoenolpyruvate carboxykinase deficiency, hypoglycemia in, 640
Phosphomannose isomerase, hypoglycemia and, 632
Phosphorylase kinase deficiency, 813–815
  clinical features of, 814
  diagnosis of, 815
  management of, 815
Pima Indian youth, type 2 diabetes in, 712–717
Pituitary, anterior lobe of, imaging of, 50–52
  posterior lobe of, imaging of, 52–53
Pituitary apoplexy, 120–121
  imaging, 59–60
Pituitary carcinoma, 14
Pituitary hypoplasia, 53
Pituitary tumor transforming gene (PTTG), 4, 5, 6
Pituitary tumors, clinical presentation of, 119–120
  Cushing's disease, diagnosis of, **191–210**
  medical therapy of, **211–222**
  differential diagnosis of sellar masses, **81–117**
  gamma knife therapy, **133–142**
  genetics of, 3–9
  imaging of, **45–79**, 85
  medical treatment of, of acromegaly, **171–190**
    of gonadotroph and thyrotroph tumors, **223–240**
    of prolactinomas, **143–169**
  pathogenesis of, **1–12**
    candidate genes, 3–6
    familial syndromes, 7–8
    intrinsic pituitary lesions, 2
    mouse models, 6
    oncogene mutations, 2–3
    role of hypothalamus, 1–2
  pathology of, **13–43**
    clinically nonfunctioning pituitary adenomas, 31–35
    hormone excess from pituitary adenomas, adrenocorticotropin hormone, 27–30
      gonadotropin, 31
      growth hormone, 16–21
      prolactin, 21–26
      thyrotropin, 26–27
    plurihormonal adenomas, 35–36
  signs and symptoms of, 81–82
  surgical management of, **119–131**. See also *Transsphenoidal surgery.*
    choice of surgical approach, 123–124

complications, 128, 129
craniotomy, 124
gamma knife therapy, **133–142**
in gonadotroph adenomas, 226–227
in prolactinomas, 149
in thyrotroph adenomas, 232–233
indications for, 120–122
postoperative radiosurgery in, 128–129
preoperative evaluation and management for, 122–123
results of, 124–128
Plasmacytomas, 101
Plasminogen activator inhibitor–1, increased activity of, in insulin resistance, 447–449, 452–453
Platelet dysfunction, in carbohydrate intolerance, in polycystic ovary syndrome, 446–447
Plurihormonal pituitary adenomas, 35–36
Polycystic ovary syndrome, acanthosis nigricans in, 403
acne in, 398
adrenal dysfunction in, **265–293**
androgenetic alopecia in, 410–411, 418
anovulation in. See *Anovulation.*
beta cell dysfunction in, 346–347, 424, 427–428
cancer in, 255–259
breast, 257–259
endometrial, 256–257
ovarian, 258
cardiovascular disease in, 251–253, **439–458**
clinical features of, 397–399
criteria for, 380–382
definition of, 380
diabetes mellitus in. See *Diabetes mellitus, in polycystic ovary syndrome.*
diagnosis of, **397–408**
criteria for, 380–382
differential diagnosis of, 400–402, 406
epidemiology of, **247–263**
ethnic differences in, 249
evaluation of, 402–406
genetic studies of, 354–356, **379–396**
glucose intolerance in. See *Diabetes mellitus; Glucose intolerance.*
gonadotropin secretion in, 297–301
androgens and, 308–309
estrogen-progesterone feedback and, 310–316
estrogens and, 308
hypothalamic regulation and, 307–309, 313, 317–318
in adolescence, 301–303, 317–318
mechanisms of, 302, 304–306
neurotransmitters and, 307–308
pulsatile, 299–301, 304–306, 313, 317–318
growth factor action in, **325–339**, 353–354
hirsutism in. See *Hirsutism.*
history of, 402–403
hormonal profile in, 399–400
hyperandrogenism in. See *Hyperandrogenism.*
hypercholesterolemia in, 250–251, 440–442
treatment of, 450–451
hyperinsulinism in. See *Hyperinsulinism.*
hypertension in, 251, 441
pregnancy-induced, 255
treatment of, 451
in adolescents, 301–302, 317–318
insulin action in, 309–310
in ovary, **341–359**, **361–378**
insulin-like growth factor family action in, **325–339**, 353–354
insulin resistance in. See *Insulin, resistance to, in polycystic ovary syndrome.*
laboratory studies of, 403–405
male relative disorders related to, 383, 385–386
metabolic profile in, 399–400
neuroendocrine aspects of, **295–324**
obesity in. See *Obesity, in polycystic ovary syndrome.*
occult, 248
ovarian function in, **265–293**
growth factor action on, **325–339**, 353–354
insulin action on, **361–378**
phenotypic studies of, **379–396**
criteria for, 380–381
versus normal criteria, 382
in sisters, 387–391
literature review of, 382–387
physical examination in, 403
predisposing factors for, 248–249
pregnancy in, problems with, 254–255, 398–399
prevalence of, 247–248
treatment of, antiandrogenic, **409–421**
for cardiovascular disease risk reduction, 449–453
insulin-lowering, **423–438**, 452–453
twin studies of, 386–387
Positron emission tomography, 64
Precocious puberty, central, **901–918**
natural history of, 905
treatment of, criteria for, and rationale for, 907–915
fertility following, 912
goals of, 909–910
gonadotropin-releasing hormone analogues for, 908–912
growth and adult height following, 912–913, 914, 915
indications for, 907–908
monitoring of, 910–912
physiologic status after, 912

Precocious puberty *(Continued)*
definition of, 904
diagnosis and assessment of, criteria for, 905–907
progressive, growth rate and, 906
skeletal maturation and, 906
slowly progressive, 904
types of, 904–905
Precursor cell adenomas, 33
Preeclampsia, in polycystic ovary syndrome, 255
Pregnancy, dopamine agonists in, 158–161
in polycystic ovary syndrome, diabetes mellitus in, 254–255
hypertension in, 255
problems with, 398–399
Primitive germ cell tumors, parasellar, 93–95
Progesterone, in gonadotropin regulation, in polycystic ovary syndrome, 310–316
secretion of, insulin effects on, 366–367, 371–372
in polycystic ovary syndrome, 367–368
Prolactin, excess of, from pituitary adenomas, 21–26
in polycystic ovary syndrome, 404
secretion, neuroendocrine regulation of, 143–145
Prolactinomas, **143–169.** See also *Hyperprolactinemia.*
diagnosis of, 148
imaging of, 56
pathogenesis and natural history of, 147–148
signs and symptoms of, 83
treatment of, efficacy of various modes, 150
medical, bromocriptine, 150–156
other dopamine agonists, 156–158
pregnancy and dopamine agonists, 158–161
observation in, 148–149
radiotherapy in, 150
surgical, 121, 122, 127–128, 149
Prolonged (72-hour) fast, in healthy appearing patient, 520–527
Propranolol, hypoglycemic action of, 568
Protein deficiency, mitochondrial trifunctional, hypoglycemia in, 631
PTTG (pituitary tumor transforming gene), in pituitary tumors, 4, 5, 6
Puberty, age of onset of, 903–904
changes of, progression of, 905–906
normal, physiology, growth, and maturity in, 901–904
precocious. See *Precocious puberty, central.*
role of leptins in, 760
Pyruvate carboxylase deficiency, hypoglycemia in, 639

Quinagolide, in acromegaly, 182, 183
in prolactinomas, 152, 157
Quinine, hypoglycemia induced by, 567

Radiosurgery, stereotactic, for pituitary adenomas, 134
for pituitary tumors. See also *Gamma knife therapy.*
after surgery, 128–129
Radiotherapy, for gonadotroph adenomas, 227
for pituitary adenomas, 134
complications of, 139–140
for prolactinomas, 150
for thyrotroph adenomas, 233
Rathke's cleft cysts, 53, 65, 87–89
Retinopathy, diabetic, 866–867
screening for, in adolescents with type 1 diabetes, 874–875
Reye's syndrome, hypoglycemia in, 640–641
Ritanserin, in Cushing's disease, 213

Salicylate poisoning, hypoglycemia in, 640
Salicylates, hypoglycemic effect of, 569
Sarcoidosis, pituitary adenoma versus, 104–105
Schwannomas, 101–102
Sella, empty, 65–68
Sellar masses, classification of nonpituitary lesions, 83
differential diagnosis of, **81–117**
aneurysms, 102–103
chordomas, 91–93
cysts, 85–90
data on patients undergoing transsphenoidal surgery, 82
dermoid tumors, 95
granulomatous, inflammatory, and infectious processes, 103–109
hyperplasia of pituitary gland, 110–111
hypothalamic glioma, 96–97
miscellaneous tumors, 100–102
optic nerve glioma, 95–96
parasellar meningioma, 97–99
pituitary metastases, 99–100
primitive germ cell tumors, 93–95
sphenoid sinus mucocele, 109–110
nonpituitary, signs and symptoms of, 83–84
signs and symptoms of, 81–84
Sellar region, imaging of, **45–79,** 85
Serotonin antagonists, in Cushing's disease, 212–213
Sheehan's syndrome, 59
Silent subtype III adenoma, 35–36

Skeleton, age of, growth and growth potential in relation to, 906
maturation of, precocious puberty and, 906
Smoking, and type 1 diabetes, 872
SMS 201–995. See *Octreotide.*
Sodium valproate, in Cushing's disease, 214
Somatostatin analogues, in acromegaly, long-acting, 177–178
octreotide, 172–177
primary versus secondary therapy, 178–181
in Cushing's disease, 214
in gonadotroph adenomas, 227–229
in thyrotroph adenomas, 233–234
Somatotroph adenomas, 17
Somatotroph hyperplasia, 20–21
Spermarche, early, in central precocious puberty, therapy of, 909
Sphenoid sinus mucoceles, 109–110
Spironolactone, in hirsutism, in polycystic ovary syndrome, 413–415
Stereotactic radiosurgery, for pituitary adenomas, 134
for pituitary tumors. See also *Gamma knife therapy.*
after surgery, 128–129
Steroid hormones, secretion of, pubertal gonadotropin and, 905
serum leptin concentrations and, 753, 754–755, 756, 757–759
synthesis of, 265–268
Stromal cells, ovarian, insulin effects on, 375
Substrates, in glucose counterregulation, 480, 487–488
Sugar bowl, controlling of, **663–694**
Suicide, and attempted suicide, patients alive following insulin for, 588–590
patients dead following insulin for, 590
from self-induced hypoglycemia, 580, 581, 584, 585–586, 588–591
using sulfonylureas, 591
Sulfonylurea(s), 562
factitious hypoglycemia induced by, 582–583
hypoglycemia induced by. See *Hypoglycemia, sulfonylurea-induced.*
overdose of, diazoxide in, 593
octreotide in, 593
second generation, 562
suicide using, 591
SUR1 genes, mutations of, and autosomal recessive hyperinsulinemic hypoglycemia, 649–650

Testosterone, excess of, in polycystic ovary syndrome, 399–400, 403–404
cardiovascular risks in, 444
inhibitors of. See *Antiandrogens.*
insulin resistance related to, 352
synthesis of, 265–268, 272
Theca cells, androgen synthesis in, 268–270
in polycystic ovary syndrome, 273–275, 278–279
insulin effects on, in polycystic ovary syndrome, 373–375
Thiazolidinediones, in hyperinsulinemia, in polycystic ovary syndrome, 428, 434–436, 452–453
13q14, in pituitary tumors, 4
Thyroid-stimulating hormone, in thyrotroph adenomas, 230–232
Thyrotroph adenomas, 26, 230
clinical presentation of, 231
evaluation of, 232
hormonal classification of, 230–231
treatment of, medical, 233–234
radiation, 233
surgical, 232–233
Thyrotroph hyperplasia, 25, 27
Thyrotropin excess, from pituitary adenomas, 26–27
Tolbutamide, 562
Transsphenoidal surgery, 124
approach for, 125
clinical entities treated by, 120, 122
complications of, 128, 129
diagnoses in patients undergoing, 82
for prolactinomas, 150
pituitary adenomas treated by, 120
results of, 124–128
Troglitazone, in hyperinsulinemia, in polycystic ovary syndrome, 428, 434–436, 452
Tryptophan, hypoglycemia induced by, 570
Tuberculosis, pituitary adenoma versus, 103
Tumor necrosis factor-α, in insulin resistance, 349
Tumor(s), androgen-producing, versus polycystic ovary syndrome, 401–402, 404, 406
non-islet cell, hypoglycemia in, 628–629
Tyrosinemia, hereditary, hypoglycemia in, 636

Ultrasonography, endoscopic, in localization of insulinomas, 542
in polycystic ovary syndrome, 405
intraoperative, in localization of insulinomas, 542–543
preoperative transabdominal, in localization of insulinomas, 541–542
Urine free cortisol, in Cushing's syndrome diagnosis, 191–192, 193

Uterus, cancer of, in polycystic ovary syndrome, 256–257

Vascular lesions, in sellar region imaging, 71–72
Vasoactive intestinal peptide, prolactin secretion and, 145
Vasopressin, 53, 84
Venous sampling, hepatic, arterial calcium stimulation with, in localization of insulinomas, 540, 541
  transhepatic portal, for localization of insulinomas, 539–540
Visual field defects, pituitary surgery and, 124–125
Visual function, octreotide and, 229
Visual loss, in sellar/parasellar nonpituitary lesions, 84
Vitamin D, biosynthesis of, genetic disorders of, **825–840**
  pathway of, 825–827
  forms of, 825
Vitamin D 24-hydroxylase, 827, 828–829
Vitamin D 25-hydroxylase, 827, 828
Vitamin D 1α-hydroxylase, 827, 829–834
  deficiency of, molecular genetics of, 834–838
Vitamin D biosynthetic enzymes, 827–834
von Gierke disease. See *Glucose 6-phosphatase deficiency.*

Waist-to-hip ratios, in polycystic ovary syndrome, 442
Weight loss, in polycystic ovary syndrome, 428–429, 452